Rheumatology International

, Volume 30, Issue 6, pp 749–753 | Cite as

Adherence to treatment guidelines in two primary care populations with gout

  • Geoffrey C. WallEmail author
  • Carrie F. Koenigsfeld
  • Karly A. Hegge
  • Michelle M. Bottenberg
Original Article


Published guidelines for the treatment of gout aim to improve the evidenced-based management of this disorder. Unfortunately, several studies suggest that these guidelines are not routinely followed in clinical practice. Limited data exist comparing different groups of primary care providers regarding compliance with published gout guidelines. We conducted a retrospective study comparing two different general internal medicine (IM) practices and evaluated compliance with these guidelines. All patients with a billing code for gout seen in two large IM clinics (Clinic A, an inner-city urban clinic, and Clinic B, a suburban clinic) between January 2004 and December 2007 were selected for chart review. Patients referred to a rheumatologist for management of gout were excluded. The care received by these patients for gout was compared to recommendations from published guidelines, with the primary outcome assessing the percentage of patients who received at least yearly monitoring of serum uric acid (SUA) levels. In both clinics, yearly monitoring of SUA levels occurred in approximately one quarter of the patients with gout (Clinic A 27.5% vs. Clinic B 28.9%, P = 0.87). Compared to SUA, renal function was monitored more frequently in each of the groups. Listed indications for antihyperuricemic therapy were similar between groups, although gouty flares were reported more frequently in clinic B (P = 0.005). In this retrospective review of gout management in two IM clinics, general care for patients with this condition did not differ significantly. However, overall compliance with recommendations from published guidelines was low.


Gout Primary Care Treatment Guidelines 


Conflict of interest statement

This study was sponsored by an unrestricted grant from Takeda Pharmaceuticals. The authors had complete control over study design, data collection and analysis, manuscript development, and the decision to publish. The authors have no other real or potential conflicts to declare.


  1. 1.
    Terkeltaub RA (2003) Gout. N Engl J Med 349:1647–1655. doi: 10.1056/NEJMcp030733 CrossRefPubMedGoogle Scholar
  2. 2.
    Arromdee E, Michet CJ, Crowson CS, O’Fallon WM, Gabriel SE (2002) Epidemiology of gout: is the incidence rising? J Rheumatol 29:2403–2406PubMedGoogle Scholar
  3. 3.
    Mikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT, Bilker WB, Saag KG (2004) Quality of care indicators for gout management. Arthritis Rheum 50:937–943. doi: 10.1002/art.20102 CrossRefPubMedGoogle Scholar
  4. 4.
    Zhang W, Doherty M, Pascual E et al (2006) EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1301–1311. doi: 10.1136/ard.2006.055251 CrossRefPubMedGoogle Scholar
  5. 5.
    Zhang W, Doherty M, Bardin T et al (2006) EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1312–1324. doi: 10.1136/ard.2006.055269 CrossRefPubMedGoogle Scholar
  6. 6.
    Sarawate CA, Brewer KK, Yang W et al (2006) Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 81:925–934. doi: 10.4065/81.7.925 CrossRefPubMedGoogle Scholar
  7. 7.
    Pal B, Foxall M, Dysart T, Carey F, Whittaker M (2000) How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 19:21–25. doi: 10.1007/s100670050005 CrossRefPubMedGoogle Scholar
  8. 8.
    Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG (2005) Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 44:1038–1042. doi: 10.1093/rheumatology/keh679 CrossRefGoogle Scholar
  9. 9.
    Sarawate CA, Patel PA, Schumacher HR et al (2006) Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 12:61–65. doi: 10.1097/01.rhu.0000209882.50228.9f CrossRefPubMedGoogle Scholar
  10. 10.
    Hanly JG, Skedgel C, Sketris I et al (2009) Gout in the elderly—a population health study. J Rheumatol 36:822–830. doi: 10.3899/jrheum.080768 CrossRefPubMedGoogle Scholar
  11. 11.
    Siegel D, Lopez J, Meier J, Goldstein MK, Lee S, Brazill BJ, Matalka MS (2003) Academic detailing to improve antihypertensive prescribing patterns. Am J Hypertens 16:508–511. doi: 10.1016/S0895-7061(03)00060-8 CrossRefPubMedGoogle Scholar
  12. 12.
    Bailey TC, Noirot LA, Blickensderfer A, Rachmiel E, Schaiff R, Kessels A, Braverman A, Goldberg A, Waterman B, Dunagan WC (2007) An intervention to improve secondary prevention of coronary heart disease. Arch Intern Med 167:586–590. doi: 10.1001/archinte.167.6.586 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Geoffrey C. Wall
    • 1
    • 2
    Email author
  • Carrie F. Koenigsfeld
    • 1
    • 3
  • Karly A. Hegge
    • 4
  • Michelle M. Bottenberg
    • 1
    • 5
  1. 1.College of Pharmacy and Health SciencesDrake UniversityDes MoinesUSA
  2. 2.Iowa Methodist Medical CenterDes MoinesUSA
  3. 3.Lakeview Internal Medicine ClinicDes MoinesUSA
  4. 4.College of PharmacySouth Dakota State UniversityBrookingsUSA
  5. 5.VA Medical CenterDes MoinesUSA

Personalised recommendations